SCHEMBL9628212

SCHEMBL9628212

CO[C@@H](Cc1ccccc1)C(=O)O

nearest known ligand 0.70

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
SRR Q9GZT4 3/20 0.70
PPARG P37231 17/20 0.65
PPARA Q07869 15/20 0.65
PPARD Q03181 3/20 0.63
PSAT1 Q9Y617 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16877217 1.00 SRR (0.70) SRRPPARGPPARAPPARDPSAT1
SCHEMBL2517934 1.00 SRR (0.70) SRRPPARGPPARAPPARDPSAT1
SCHEMBL8091095 0.86 SRR (0.58) SRRPPARGPPARAPPARD
SCHEMBL12141661 0.86 SRR (0.58) SRRPPARGPPARAPPARD
SCHEMBL5606931 0.86 PPARA (0.74) PPARGPPARAPPARD
SCHEMBL4780746 0.85 SRR (0.61) SRRPPARGPPARAPPARDPSAT1
SCHEMBL7150900 0.85 SRR (0.56) SRRPPARGPPARAPPARD
Hydrochloric Acid SCHEMBL5754335 0.85 SRR (0.61) SRRPPARGPPARAPPARDPSAT1
SCHEMBL4451311 0.85 PPARA (0.56) SRRPPARGPPARAPPARDPSAT1
SCHEMBL3466702 0.85 PPARA (0.56) SRRPPARGPPARAPPARDPSAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12415835-B2 Peptide-compound cyclization method CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-09-16 US disclosed
US-20240166689-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-05-23 US disclosed
US-11891457-B2 Peptide-compound cyclization method CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-02-06 US disclosed
US-20230399297-A1 Novel Glutamine Analogs JACOBIO PHARMACEUTICALS CO., LTD (CN) 2023-12-14 US disclosed
US-20230158179-A1 RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF RAYZEBIO, INC. 2023-05-25 US disclosed
WO-2022078416-A1 NOVEL GLUTAMINE ANALOGS JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2022-04-21 WO disclosed
EP-3974563-A1 CYCLIC PEPTIDES Chugai Seiyaku Kabushiki Kaisha (JP) 2022-03-30 EP disclosed
EP-2813512-B1 PEPTIDE-COMPOUND CYCLIZATION METHOD CHUGAI PHARMACEUTICAL CO LTD (JP) 2021-03-31 EP disclosed
US-20210061860-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2021-03-04 US disclosed
US-20210061860-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2021-03-04 US disclosed
US-20150080549-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-03-19 US disclosed
US-20150080549-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-03-19 US disclosed
EP-2813512-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD Chugai Seiyaku Kabushiki Kaisha (JP) 2014-12-17 EP disclosed
EP-2813512-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD Chugai Seiyaku Kabushiki Kaisha (JP) 2014-12-17 EP disclosed
WO-2013100132-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD 中外製薬株式会社 (JP) 2013-07-04 WO disclosed
US-20090175792-A1 GLYCOMIMETIC INHIBITORS OF SIGLEC-8 GLYCOMIMETICS, INC. (US) 2009-07-09 US disclosed
US-20090175792-A1 GLYCOMIMETIC INHIBITORS OF SIGLEC-8 GLYCOMIMETICS, INC. (US) 2009-07-09 US disclosed
EP-0334845-B1 LIQUID CRYSTAL COMPOUNDS, MIXTURES AND DEVICES The Secretary of State for Defence in Her Britannic Majesty's Government of the United Kingdom of Great Britain and (GB) 1992-05-06 EP disclosed
US-5037576-A Ferroelectric; increased polarization THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) 1991-08-06 US disclosed
WO-1988002390-A2 LIQUID CRYSTAL COMPOUNDS, MIXTURES AND DEVICES THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNI (GB) 1988-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11891457-B2 Peptide-compound cyclization method VIP, NGLY1, GLP1R SRR 3833/4885PPARG 3973/4885PPARA 3215/4885
US-20210061860-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD VIP, NGLY1, GLP1R SRR 3833/4885PPARG 3973/4885PPARA 3215/4885
US-20240166689-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD VIP, NGLY1, GLP1R SRR 3833/4885PPARG 3973/4885PPARA 3215/4885
US-20230399297-A1 Novel Glutamine Analogs GLUL, GATD3, GLS SRR 3147/4885PPARG 1211/4885PPARA 1857/4885
US-20090175792-A1 GLYCOMIMETIC INHIBITORS OF SIGLEC-8 SIGLEC7, SIGLEC9, FUT8 SRR 3387/4885PPARG 4434/4885PPARA 4689/4885
US-20150080549-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD VIP, NGLY1, GLP1R SRR 3833/4885PPARG 3973/4885PPARA 3215/4885
US-20230158179-A1 RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF PAICS, LNPEP, DNPEP SRR 2304/4885PPARG 2794/4885PPARA 2801/4885
US-12415835-B2 Peptide-compound cyclization method VIP, NGLY1, GLP1R SRR 3833/4885PPARG 3973/4885PPARA 3215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.